New autism therapy shows surprising benefits even in adult mice
sciencedaily.com
This article is written in English. Research demonstrates that inhibiting the Slc6a20a/SLC6A20 glycine transporter restores NMDA receptor function and improves behavioral deficits in adult mouse models and human brain organoids with autism-related mutations. The study indicates that targeting this specific transporter offers a precise therapeutic approach for neurodevelopmental disorders by correcting abnormal synaptic signaling without affecting other critical brain functions.
All articles from 8 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.